Alkermes Plc (ALKS NASDAQ) stock market data APIs
$41.6043
0.86(2.1%)
as of October 6, 2026
Try our APIs with
free plan!
Alkermes Plc Financial Data Overview
Price chart is built with
Anychart
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Prev. Close
41.6043
Open
42.468
High
42.8845
Low
41.5455
52 wk Range
27-55.67
Market Cap
6 987 M
P/E Ratio
112.5676
Shares Outstanding
168 M
Revenue
1 668 M
EPS
0.52
Beta
0.273
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Alkermes Plc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Alkermes Plc data using free add-ons & libraries
Get Alkermes Plc Fundamental Data
Alkermes Plc Fundamental data includes:
- Net Revenue: 1 668 M
- EBITDA: 285 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-07-28
- EPS/Forecast: -0.04
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Alkermes Plc News
New
Why Baird Sees Promising Growth Potential in Alkermes plc (ALKS)
Baird Equity Asset Management recently released its "Small/Mid Cap Growth Strategy" second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund benefited from a sharp re...
LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now?
Liquidia Corporation LQDA and Alkermes plc ALKS are both commercial-stage biopharmaceutical companies with specialty therapies and a similar mid-cap biotech investor profile. LQDA is focused on devel...
Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works?
Alkermes plc (NASDAQ:ALKS) reported on September 21 that adults receiving the investigational oral drug ALKS 7290 showed improved symptoms of attention-deficit hyperactivity disorder (ADHD). After 14 ...
Why Alkermes (ALKS) Is Down 6.0% After First ADHD Data For Orexin Agonist ALKS 7290
In September 2026, Alkermes plc reported positive topline results from a phase 1b proof-of-concept study of ALKS 7290, an investigational orexin 2 receptor agonist, which showed clinically meaningful,...
Get Alkermes Plc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.